Why Should MoonLake Immunotherapeutics (MLTX) Be In Your Portfolio?

MoonLake Immunotherapeutics (NASDAQ:MLTX) has a beta value of 1.23 and has seen 2.25 million shares traded in the recent trading session. The company, currently valued at $3.14B, closed the recent trade at $48.85 per share which meant it gained $7.69 on the day or 18.67% during that session. The MLTX stock price is -19.26% off its 52-week high price of $58.26 and 35.68% above the 52-week low of $31.42. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.24 million shares traded. The 3-month trading volume is 413.10K shares.

The consensus among analysts is that MoonLake Immunotherapeutics (MLTX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.

MoonLake Immunotherapeutics (NASDAQ:MLTX) trade information

Over the past 30 days, the shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have changed 15.42%. Short interest in the company has seen 6.04 million shares shorted with days to cover at 14.36.

Wall Street analysts have a consensus price target for the stock at $67, which means that the shares’ value could jump 27.09% from the levels at last check today.. The projected low price target is $67.0 while the price target rests at a high of $67.0. In that case, then, we find that the latest price level in today’s session is -37.15% off the targeted high while a plunge would see the stock gain -37.15% from the levels at last check today..

MoonLake Immunotherapeutics (MLTX) estimates and forecasts

The company’s shares have lost -9.95% over the past 6 months.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -319.65% over the past 5 years. Earnings growth for 2025 is a modest -51.97% while over the next 5 years, the company’s earnings are expected to decrease by -26.36%.

MLTX Dividends

MoonLake Immunotherapeutics is expected to release its next earnings report on 2025-May-11 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

MoonLake Immunotherapeutics (NASDAQ:MLTX)’s Major holders

Insiders own 15.34% of the company shares, while shares held by institutions stand at 96.89% with a share float percentage of 114.45%. Investors are also buoyed by the number of investors in a company, with MoonLake Immunotherapeutics having a total of 200.0 institutions that hold shares in the company. The top two institutional holders are BVF INC/IL with over 21.75 million shares worth more than $956.4 million. As of 2024-06-30, BVF INC/IL held 34.7258% of shares outstanding.

The other major institutional holder is CORMORANT ASSET MANAGEMENT, LP, with the holding of over 8.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $373.49 million and represent 13.5609% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are T. Rowe Price Health Sciences Fund, Inc. and Fidelity Select Portfolios-Health Care Portfolio . As of Mar 31, 2025 , the former fund manager holds about 2.02% shares in the company for having 1.28 shares of worth $62.9 million while later fund manager owns 752.79 shares of worth $36.89 million as of Mar 31, 2025 , which makes it owner of about 1.19% of company’s outstanding stock.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.